Past, presence, and future of allergen immunotherapy vaccines

Allergen-specific immunotherapy (AIT) is an allergen-specific form of treatment for patients suffering from immunoglobulin E (IgE)-associated allergy; the most common and important immunologically mediated hypersensitivity disease. AIT is based on the administration of the disease-causing allergen with the goal to induce a protective immunity consisting of allergen-specific blocking IgG antibodies and alterations of the cellular immune response so that the patient can tolerate allergen contact. Major advantages of AIT over all other existing treatments for allergy are that AIT induces a long-lasting protection and prevents the progression of disease to severe manifestations. AIT is cost effective because it uses the patient´s own immune system for protection and potentially can be used as a preventive treatment. However, broad application of AIT is limited by mainly technical issues such as the quality of allergen preparations and the risk of inducing side effects which results in extremely cumbersome treatment schedules reducing patient´s compliance. In this article we review progress in AIT made from its beginning and provide an overview of the state of the art, the needs for further development, and possible technical solutions available through molecular allergology. Finally, we consider visions for AIT development towards prophylactic application. © 2020 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd

Dorofeeva Y.1 , Shilovskiy I.2 , Tulaeva I.1, 3 , Focke-Tejkl M.1 , Flicker S.1 , Kudlay D.2 , Khaitov M.2 , Karsonova A.3 , Riabova K.3 , Karaulov A.3 , Khanferyan R. 4 , Pickl W.F.5 , Wekerle T.6 , Valenta R.1, 2, 3
Munksgaard International Publishers
  • 1 Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
  • 2 National Research Center, Institute of immunology, FMBA of Russia, Moscow, Russian Federation
  • 3 Department of Clinical Immunology and Allergy, Laboratory of Immunopathology, Sechenov First Moscow State Medical University, Moscow, Russian Federation
  • 4 Department of Immunology and Allergy, Russian People’s Friendship University, Moscow, Russian Federation
  • 5 Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
  • 6 Section of Transplantation Immunology, Department of Surgery, Medical University of Vienna, Vienna, Austria
Ключевые слова
allergen; allergen-specific immunotherapy; allergy; molecular allergy vaccines
Дата создания
Дата изменения
Постоянная ссылка

Другие записи

Suponeva N.A., Yusupova D.G., Ilyina K.A., Melchenko D.A., Butkovskaya A.A., Zhirova E.S., Taratukhina A.S., Zimin A.A., Zaitsev A.B., Klochkov A.S., Lyukmanov R.Kh., Kotov-Smolensky A.M., Khizhnikova A.E., Gatina G.A., Kutlubaev M.A., Piradov M.A.
Анналы клинической и экспериментальной неврологии. Закрытое акционерное общество "РКИ Соверо пресс". Том 14. 2020. С. 89-96